NCT06046313View on ClinicalTrials.gov

Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 19, 2023

Primary Completion Date

October 19, 2025

Study Completion Date

October 19, 2026

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

Decitabine for Injection

6mg/m2, ivgtt qd d1-10

DRUG

VENCLYXTO

100mg p.o.d1, 200mg p.o.d2, 400mg p.o.d3-21,adjust by blood concentration

Trial Locations (1)

310003

RECRUITING

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

First Affiliated Hospital of Zhejiang University

OTHER